"Biden’s COVID ‘rebound’ after treatment with Paxlovid serves as a reminder that the antiviral can have that rare outcome; The CDC still recommends Paxlovid for patients at risk of developing severe disease" - MarketWatch 8.1.22 - SCW Newswatch
MarketWatch reports on how Covid-19 sufferers treated with antiviral Paxlovid can still have relapses, as happened with President Joe Biden.
".... Paxlovid, which was developed by Pfizer Inc. PFE, +0.20%, can cause a rebound case of the virus that leads patients to test positive again two to eight days after testing negative, as MarketWatch has reported. In some cases, symptoms recur .... 'A brief return of symptoms may be part of the natural history of SARS-CoV-2 (the virus that causes COVID-19) infection in some persons, independent of treatment with Paxlovid and regardless of vaccination status,' the Centers for Disease Control and Prevention said back in May. ..."
Click here for: "Biden’s COVID ‘rebound’ after treatment with Paxlovid serves as a reminder that the antiviral can have that rare outcome; The CDC still recommends Paxlovid for patients at risk of developing severe disease" - MarketWatch 8.1.22 - SCW Newswatch
Key Words: Biden, Coronavirus, Covid-19, Paxlovid, Pandemic, Health, Medical
[please be sure to consider clicking the support button, to support this web project and related efforts]
Any health-related, legal, scientific, investment- or business-related, or other content provided on these site(s) or domain(s) is for informational purposes only, and/or to invite further reflection, research and analysis, and not for the purpose of providing medical, legal or any other kind of professional advice. All investment activity can carry risk, and these sites and domains assert no opionion or guidance regarding any investor's undertaking of any investment decision. Under no circumstances do these sites or domain(s), establish an attorney-client relationship or any similar or analogous type of relationship, professional or otherwise. Use of these site(s) and domain(s) is only permitted under, and constitutes agreement with, those or similar conditions and limitations, as expressed now, or as might be revised in the future.